drugset
Drugs / Inosine pranobex
last change Dec 2020 re-read 9 days ago

Inosine pranobex

also known as Isoprinosine
Developed for
HIV infectious disease · lymphatic system disorder · COVID-19 · respiratory tract infectious disorder
Investigated by
Newport Pharmaceuticals International · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 7

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00000699 — HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase not applicable6 trials
— NCT00002061 — HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
— NCT00002295 — HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
— NCT00002297 — HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
— NCT00002059 — HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
— NCT00002060 — HIV infectious disease Newport Pharmaceuticals International Completed No outcome recorded
— NCT00002296 — HIV infectious disease, lymphatic system disorder Newport Pharmaceuticals International Completed No outcome recorded
Comparator or background therapy2 trials
Phase 3 NCT04360122 Comparator May → Nov 2020 COVID-19 Ain Shams University Unknown No outcome recorded
Phase 3 NCT04383717 Comparator May → Aug 2020 respiratory tract infectious disorder Cairo University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Inosine pranobex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002295 ↗
6

NCT00002061 ↗

NCT00002296 ↗

NCT00002297 ↗

NCT00000699 ↗

NCT00002059 ↗

NCT00002060 ↗
Known as Isoprinosine “The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS.” NCT00002060 ↗
2

NCT04383717 ↗

NCT04360122 ↗
Route Oral “All patients take INPX capsules 4 times a day and RBV capsules 2 or 3 times a day.” NCT00000699 ↗